Repurposing with a Difference

被引：156

作者：

Boguski, Mark S. ^{[1
,2
]}

Mandl, Kenneth D. ^{[2
,3
]}

Sukhatme, Vikas P. ^{[4
]}

机构：

[1] Harvard Univ, Sch Med, Dept Pathobiol, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA

[2] Harvard Univ, Sch Med, Ctr Biomed Informat, Boston, MA 02115 USA

[3] Harvard Univ, Sch Med, Childrens Hosp Informat Program Harvard MIT, Div Hlth Sci & Technol, Boston, MA 02115 USA

[4] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA

来源：

关键词：

JANUARY-1; FEBRUARY; 2005; DRUG DEVELOPMENT; ABANDONED DRUGS; PHARMACOVIGILANCE; COMMERCIALIZE; PHILADELPHIA; IDENTIFY; DEVELOP; USA; PA;

D O I：

10.1126/science.1169920

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

引用

页码：1394 / 1395

页数：2

共 28 条

[1] Estimating the cost of new drug development: Is it really $802 million?
Adams, CP
Brantner, VV
[J]. HEALTH AFFAIRS, 2006, 25 (02) : 420 - 428
[2] Drug repositioning: Identifying and developing new uses for existing drugs
Ashburn, TT
Thor, KB
[J]. NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (08) : 673 - 683
[3] Boguski MS, 2009, GENOMIC AND PERSONALIZED MEDICINE, VOL 1, P252
[4] The Medical Dictionary for Regulatory Activities (MedDRA)
Brown, EG
Wood, L
Wood, S
[J]. DRUG SAFETY, 1999, 20 (02) : 109 - 117
[5] The Tell-Tale Heart: Population-Based Surveillance Reveals an Association of Rofecoxib and Celecoxib with Myocardial Infarction
Brownstein, John S.
Sordo, Margarita
Kohane, Isaac S.
Mandl, Kenneth D.
[J]. PLOS ONE, 2007, 2 (09):
[6] Carley DW, 2005, IDRUGS, V8, P310
[7] Carley DW, 2005, IDRUGS, V8, P306
[8] Christensen C.M., 2009, INNOVATORS PRESCRIPT
[9] The price of innovation: new estimates of drug development costs
DiMasi, JA
Hansen, RW
Grabowski, HG
[J]. JOURNAL OF HEALTH ECONOMICS, 2003, 22 (02) : 151 - 185
[10] Eisenberg Rebecca S, 2005, Yale J Health Policy Law Ethics, V5, P717